CareDx, a molecular diagnostics company, has entered into a multi-year supply agreement with Illumina that will provide access to next generation sequencing, microarray equipment and consumables to the CareDx reference and R&D laboratories.
CareDx president and CEO Peter Maag said: "As we expand our pipeline of high-value, transplant diagnostic surveillance solutions from the gene expression-based AlloMap(R) to cell-free DNA-based tests, we believe the technology solutions from Illumina will effectively support our development and commercialization efforts."
AlloMap MolecularTesting is a non-invasive gene expression test used to aid in the identification of heart transplant recipients who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap is performed in the XDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the US Food and Drug Administration in 2008 and was CE marked for the European Union in 2011.
Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.